Table 2.
HbA1c and weight change among propensity score-matched cohorts of EQW or BI initiators (with no prior use of an injectable diabetic medication), stratified by race: 1 January 2012 to 31 January 2015, Optum Electronic Health Record Research Database
| White | Black/African American | Other | |||||
|---|---|---|---|---|---|---|---|
| EQW (n = 1630) | BI (n = 3277) | EQW (n = 151) | BI (n = 303) | EQW (n = 165 | BI n = 323 | ||
| HbA1c %a | |||||||
| Baseline, mean | 8.27% (67 mmol/mol) | 8.45% (69 mmol/mol) | 8.56% (70 mmol/mol) | 8.60% (70 mmol/mol) | 8.51% (70 mmol/mol) | 8.81% (73 mmol/mol) | |
| 0–3 months, Δ (95% CI) | −5.83 (−6.97, −4.69) | −3.52 (−4.15, −2.89) | −2.80 (−5.43, −0.17) | −1.60 (−3.01, −0.19) | −4.34 (−7.45, −1.23) | −3.06 (−4.94, −1.18) | |
| 3–6 months, Δ (95% CI) | −7.97 (−9.31, −6.63) | −5.33 (−6.11, −4.55) | −6.75 (−10.80, −2.69) | −4.19 (−6.50, −1.87) | −6.85 (−10.88, −2.82) | −5.01 (−7.49, −2.54) | |
| 6–9 months, Δ (95% CI) | −7.40 (−8.77, −6.03) | −4.82 (−5.61, −4.03) | −7.12 (−11.54, −2.70) | −3.59 (−5.87, −1.31) | −6.16 (−10.33, −1.99) | −4.76 (−7.33, −2.18) | |
| 9–12 months, Δ (95% CI) | −6.89 (−8.29, −5.50) | −4.68 (−5.51, −3.86) | −5.99 (−10.33, −1.65) | −3.11 (−5.37, −0.85) | −5.26 (−9.40, −1.13) | −4.34 (−6.98, −1.71) | |
| Weight changea | |||||||
| Baseline, mean kg | 108.61 | 108.50 | 110.53 | 110.19 | 97.58 | 96.31 | |
| 0–3 months, Δ (95% CI) | −0.81 (−1.25, −0.38) | 0.02 (−0.03, 0.07) | −0.55 (−1.72, 0.63) | −0.03 (−0.21, 0.16) | −0.28 (−1.09, 0.53) | 0.24 (−0.29, 0.78) | |
| 3–6 months, Δ (95% CI) | −1.31 (−1.87, −0.75) | 0.19 (0.04, 0.34) | −0.89 (−2.41, 0.63) | −0.07 (−0.38, 0.24) | −0.63 (−1.89, 0.63) | 0.37 (−0.32, 1.05) | |
| 6–9 months, Δ (95% CI) | −1.52 (−2.17, −0.88) | 0.16 (0.01, 0.31) | −1.08 (−2.86, 0.70) | 0.11 (−0.29, 0.51) | −0.80 (−2.34, 0.74) | 0.00 (−0.06, 0.06) | |
| 9–12 months, Δ (95% CI) | −1.73 (−2.45, −1.02) | 0.17 (0.01, 0.33) | −1.11 (−3.02, 0.81) | 0.08 (−0.29, 0.44) | −1.43 (−3.63, 0.77) | −0.09 (−0.48, 0.30) | |
| Body mass indexa | |||||||
| Baseline, mean kg/m2 | 37.01 | 37.52 | 37.58 | 36.35 | 36.52 | 34.67 | |
| 0–3 months, Δ (95% CI) | −0.96 (−1.43, −0.48) | −0.23 (−0.40, −0.07) | −0.77 (−2.17, 0.62) | −0.28 (−0.87, 0.31) | −0.90 (−2.34, 0.54) | −0.12 (−0.51, 0.26) | |
| 3–6 months, Δ (95% CI) | −1.50 (−2.10, −0.90) | −0.12 (−0.24, 0.00) | −1.01 (−2.63, 0.61) | −0.35 (−1.03, 0.33) | −1.27 (−3.06, 0.52) | −0.05 (−0.29, 0.20) | |
| 6–9 months, Δ (95% CI) | −1.64 (−2.31, −0.98) | −0.15 (−0.30, −0.01) | −1.07 (−2.83, 0.70) | −0.25 (−0.85, 0.36) | −1.61 (−3.78, 0.57) | −0.51 (−1.37, 0.35) | |
| 9–12 months, Δ (95% CI) | −1.77 (−2.49, −1.04) | −0.23 (−0.42, −0.04) | −1.19 (−3.17, 0.79) | −0.54 (−1.49, 0.41) | −1.69 (−4.08, 0.70) | −0.43 (−1.27, 0.42) | |
| HbA1c <7 and any weight loss, N (%)a | |||||||
| 0–3 months, N (%) | 368 (22.6) | 411 (12.5) | 22 (14.6) | 34 (11.2) | 26 (15.9) | 29 (9.1) | |
| 3–6 months, N (%) | 423 (26.0) | 459 (14.0) | 33 (22.0) | 37 (12.2) | 29 (17.9) | 35 (10.7) | |
| 6–9 months, N (%) | 366 (22.5) | 405 (12.4) | 26 (17.2) | 35 (11.4) | 26 (15.5) | 31 (9.7) | |
| 9–12 months, N (%) | 334 (20.5) | 361 (11.0) | 27 (17.9) | 30 (9.8) | 20 (12.1) | 24 (7.5) | |
EQW exenatide once weekly, BI basal insulin, Δ: percent change from baseline
aAll measures are adjusted for age, gender, smoking status, baseline measures (HbA1c, BMI, HDL, LDL), and sulfonylurea use